Your search for ganciclovir returned 6 results

Although valganciclovir is an effective CMV prophylactic agent after kidney transplantation, it is associated with significant side effects.

The new approvals include Besremi, Fyarro, Livtencity, Voxzogo, and Vuity.

Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates.

Maribavir is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates.

The NDA submission is supported by data from the multicenter, randomized, open-label, active-controlled phase 3 TAK-620-303 (SOLSTICE) trial.

Foscarnet sodium injection is indicated to treat cytomegalovirus retinitis in patients with AIDS and acyclovir-resistant mucocutaneous HSV in immunocompromised patients.